Related references
Note: Only part of the references are listed.Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration- Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide
Emmanuel S. Antonarakis et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A Novel High Content Imaging-Based Screen Identifies the Anti-Helminthic Niclosamide as an Inhibitor of Lysosome Anterograde Trafficking and Prostate Cancer Cell Invasion
Magdalena L. Circu et al.
PLOS ONE (2016)
Persistent androgen receptor addiction in castration-resistant prostate cancer
Michael T. Schweizer et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Niclosamide Suppresses Cell Migration and Invasion in Enzalutamide Resistant Prostate Cancer Cells via Stat3-AR Axis Inhibition
Chengfei Liu et al.
PROSTATE (2015)
NF-κB Gene Signature Predicts Prostate Cancer Progression
Renjie Jin et al.
CANCER RESEARCH (2014)
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer
Kai-Hsiung Chang et al.
CELL (2013)
Anticancer Effects of Niclosamide in Human Glioblastoma
Anja Wieland et al.
CLINICAL CANCER RESEARCH (2013)
NF-κB2/p52 Induces Resistance to Enzalutamide in Prostate Cancer: Role of Androgen Receptor and Its Variants
Nagalakshmi Nadiminty et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B
Yu Sun et al.
NATURE MEDICINE (2012)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Development of a method by UPLC-MS/MS for the quantification of tizoxanide in human plasma and its pharmacokinetic application
Gabriel Marcelin-Jimenez et al.
BIOANALYSIS (2012)
Expression of SLCO Transport Genes in Castration-Resistant Prostate Cancer and Impact of Genetic Variation in SLCO1B3 and SLCO2B1 on Prostate Cancer Outcomes
Jonathan L. Wright et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2011)
Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants
Elahe A. Mostaghel et al.
CLINICAL CANCER RESEARCH (2011)
SLCO2B1 and SLCO1B3 May Determine Time to Progression for Patients Receiving Androgen Deprivation Therapy for Prostate Cancer
Ming Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain production
F. L. Khanim et al.
BLOOD CANCER JOURNAL (2011)
Antineoplastic Mechanisms of Niclosamide in Acute Myelogenous Leukemia Stem Cells: Inactivation of the NF-κB Pathway and Generation of Reactive Oxygen Species
Yanli Jin et al.
CANCER RESEARCH (2010)
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant
Shihua Sun et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer
Rong Hu et al.
EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM (2010)
Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer
Rong Hu et al.
CANCER RESEARCH (2009)
Screen for Chemical Modulators of Autophagy Reveals Novel Therapeutic Inhibitors of mTORC1 Signaling
Aruna D. Balgi et al.
PLOS ONE (2009)
Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance
Scott M. Dehm et al.
CANCER RESEARCH (2008)
The nuclear factor-κB pathway controls the progression of prostate cancer to androgen-independent growth
Ren Jie Jin et al.
CANCER RESEARCH (2008)
Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth
R. Bruce Montgomery et al.
CANCER RESEARCH (2008)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Intestinal cestodes
Philip Craig et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2007)
Molecular determinants of resistance to antiandrogen therapy
CD Chen et al.
NATURE MEDICINE (2004)
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways
PK Majumder et al.
NATURE MEDICINE (2004)
Share Paper
